741.00
+1.37%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Camurus
Its shares trade on Nasdaq Stockholm under the ticker CAMX.ST. It has been listed since 3 December 2015. In the fiscal year to 31 December 2025, it reported revenue of SEK 2.27bn and net income of SEK 735.6m. At that date it held total assets of SEK 4.74bn and shareholders' equity of SEK 4.24bn.
Camurus AB is a research-based pharmaceutical company. The company is headquartered in Lund, Skane. The company went IPO on 2015-12-03. The firm has a diversified research portfolio, which includes five products in clinical trials, and a number of additional product candidates in the pre-clinical phase. The Company’s product pipeline represents a mix of in-house and partnered projects in different development phases. Camurus AB is the parent company of the Group, which comprises four legal entities, namely Camurus Inc, Cubosome Inc, Camurus Development AB and Bioimplant Scandinavia AB.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 3 Dec 2015
- Employees
- 127
- Website
- camurus.com ↗
Leadership
Pay as last reported
- Mr. Per WallstroemIndependent Chairman of the BoardSEK 825,000
- Ms. Behshad SheldonPresident, since 2018SEK 350,000
- Mr. Fredrik TibergChief Executive Officer, Chief Scientific Officer, Director, since 2002SEK 36.6m
- Mr. Anders VadsholtChief Financial Officer
- Mr. Markus JohnssonSenior Vice President R and D
- Mr. Torsten MalmstroemChief Technical Officer, since 2019
- Mr. Bo Tarras-WahlbergVice President, General Counsel
- Ms. Annette MattssonVice President - Regulatory Affairs
- Ms. Agneta SvedbergVice President - Clinical Development
- Mr. Fredrik JoabssonChief Business Development Officer
- Mr. Richard JamesonChief Commercial Officer
- Ms. Maria LundqvistGlobal Head of Human Resources
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 89
- Environment
- 99
- Social
- 99
- Governance
- 69
- Direct emissions (scope 1)
- 159 t
- Energy emissions (scope 2)
- 12 t
- Value chain emissions (scope 3)
- 386 t
- Women in the workforce
- 67%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Camurus AB possesses a strong portfolio of innovative pharmaceutical products.
- The company has a well-established reputation in the industry and is trusted by healthcare professionals.
- Camurus AB has a robust and efficient manufacturing process, resulting in high-quality products.
- The company's strong financial position allows for investments in research and development.
Weaknesses
- Camurus AB may face challenges in terms of market competition and patent protection for its products.
- The company's reliance on a limited number of key customers may pose a risk to its revenue stream.
- Camurus AB's geographic presence is primarily focused on specific regions, limiting its market reach.
- The company's dependence on external suppliers for raw materials may result in potential supply chain disruptions.
Opportunities
- The growing demand for innovative pharmaceutical solutions presents opportunities for Camurus AB to expand its market share.
- Strategic partnerships and collaborations with other pharmaceutical companies can enhance Camurus AB's product development capabilities.
- Expansion into new geographic markets can provide Camurus AB with access to untapped customer segments.
- The increasing focus on personalized medicine opens avenues for the development of tailored pharmaceutical products.
Threats
- Regulatory changes and stringent approval processes may delay or hinder the launch of new products by Camurus AB.
- The presence of generic competitors in the pharmaceutical market poses a threat to Camurus AB's market share and pricing strategy.
- Rapid advancements in technology may require significant investments to keep up with industry trends.
- Economic fluctuations and healthcare budget constraints can impact the purchasing power of Camurus AB's target customers.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.